导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -12.68% | 3966/4773 |
| 近一周 | -2.55% | 4032/5465 |
| 近一月 | -2.79% | 1907/5421 |
| 近一季 | -2.63% | 1455/5231 |
| 近半年 | -4.58% | 2876/4920 |
| 近一年 | -16.16% | 3812/4394 |
| 近两年 | 30.22% | 2265/2954 |
| 近三年 | 10.85% | 1736/2253 |
| 成立以来 | 21.88% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-14.60% 4673/4961 |
8.61% 2574/5312 |
- - |
- - |
| 2025 | 3.68% 3103/4813 |
-6.64% 3378/3635 |
4.22% 828/4076 |
11.11% 3200/4524 |
-4.09% 3394/4813 |
| 2024 | 29.07% 139/3463 |
-4.65% 1731/2808 |
-8.20% 2189/3014 |
41.54% 58/3129 |
4.19% 734/3463 |
| 2023 | 3.89% 255/2656 |
4.13% 1040/2280 |
-2.81% 677/2385 |
7.18% 58/2515 |
-4.22% 920/2655 |
| 2022 | -24.75% 1253/2207 |
-17.91% 1282/1919 |
1.98% 1390/2016 |
-15.28% 1262/2113 |
6.10% 391/2208 |
| 2021 | -1.28% 792/1822 |
-13.87% 1162/1255 |
7.19% 694/1330 |
5.02% 301/1466 |
1.82% 789/1822 |
| 2020 | 22.09% 676/1250 |
-10.52% 788/1028 |
10.31% 774/1067 |
20.90% 48/1164 |
2.31% 1000/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 天弘中证全指证券公司ETF联接C VS. 长安沪深300非周期A(740101) |